{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pityriasis-versicolor/management/management/","result":{"pageContext":{"chapter":{"id":"216757cf-4ca3-5974-b742-43171690f9df","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 0159c72d-8a34-437b-8ed7-cfaa72d78cf5 --><h2>Scenario: Management</h2><!-- end field 0159c72d-8a34-437b-8ed7-cfaa72d78cf5 -->","summary":"Covers the management of pityriasis versicolor and prevention of its recurrence.","htmlStringContent":"<!-- begin item f23748a0-4d5c-4580-ad03-ba02fe5d63ed --><!-- begin field 2ba97fb9-8f46-4471-8b5e-acbc0159a04e --><p>From age 10 years onwards.</p><!-- end field 2ba97fb9-8f46-4471-8b5e-acbc0159a04e --><!-- end item f23748a0-4d5c-4580-ad03-ba02fe5d63ed -->","topic":{"id":"0fea6769-8496-527e-9900-49c0411410df","topicId":"c13665df-bfcd-4fcc-b476-7e462353856b","topicName":"Pityriasis versicolor","slug":"pityriasis-versicolor","lastRevised":"Last revised in April 2020","chapters":[{"id":"48061d3b-77de-5625-838f-3490efd16385","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a2b64334-2f3e-5682-a55c-d89347f8b48f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ce5bd4c2-7fa7-58e8-83bd-614d945b9710","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fd8be5be-8d54-5431-88b3-44c33e4401da","slug":"changes","fullItemName":"Changes"},{"id":"fc8f8e10-88b6-5879-a69c-18f87f3c8340","slug":"update","fullItemName":"Update"}]},{"id":"ef705ed5-a47f-528d-97cc-8d9af2963eb5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5fdd92bc-0340-527b-8689-d48f307ce6e3","slug":"goals","fullItemName":"Goals"},{"id":"ec48d89c-955c-5e3d-af73-6e587354a56d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ecafa7cb-70ed-551b-b6d1-ddcf4f6bed3d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fd61e511-1bf0-541e-8192-19970ba59e82","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"05312c95-9379-5709-872d-b3e10aebfcc0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b5911b4a-ad4b-52c9-9bfe-a0978bdc63c5","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"08f0e975-952b-5ec7-a211-0f0a447d63b6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d63e7392-070c-56c9-890f-bc58ae7b5b3a","slug":"definition","fullItemName":"Definition"},{"id":"1fbe5c19-2ec5-50c3-b69f-a251b7bfbd1c","slug":"causes","fullItemName":"Causes"},{"id":"2e638f9d-1d65-5294-9020-379452470ca9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c223ff1b-62e0-5bc5-bb16-aee1037798a3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"7e95bc3b-7443-5b1f-aa77-97a44859c0ee","slug":"complications","fullItemName":"Complications"}]},{"id":"5a3a3c2c-acb7-5f56-af38-2ddbcc543c8f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e5b4b862-ed72-5b87-88c3-cec73356d952","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c0059764-1025-5915-ae2c-8a71310be239","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9c584d50-0808-57d6-b5c7-cb1af47c1be2","fullItemName":"Management","slug":"management","subChapters":[{"id":"216757cf-4ca3-5974-b742-43171690f9df","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"05482fa5-1c4b-5f1b-8b8e-6137e274e4e5","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d7f1cba7-9069-572c-b52d-d9319951ed08","slug":"ketoconazole-2percent-shampoo","fullItemName":"Ketoconazole 2% shampoo"},{"id":"54569984-7427-54f7-b6cb-3522c344a0de","slug":"topical-imidazole-creams","fullItemName":"Topical imidazole creams"},{"id":"11062d95-1795-54d5-88e9-9c9d1464555e","slug":"selenium-sulphide-shampoo","fullItemName":"Selenium sulphide shampoo"},{"id":"ff895dc9-00a2-59b2-9e11-6529379ea8fd","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"95b98848-e241-56a6-b83d-380420c23440","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"}]},{"id":"9d664332-8ca1-5c9d-a030-544c2adfea31","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5609556e-dbb4-56de-8035-bced2df7d533","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8e7f4e16-d4b6-59d4-919a-6eb3a9f60a94","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a652af6c-c591-5583-ba4e-0ce6cb952e3b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e7e76cf0-a6de-51cc-9a4b-89194241dc6d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d791c177-66f7-5aaa-ab09-a2079d32f854","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"12d54e36-6600-5446-83a4-05d3c235b7f0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f54e136f-01a7-5fed-a635-fa6f209d4e3f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9c584d50-0808-57d6-b5c7-cb1af47c1be2","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"db4d48ab-f770-5cf4-b825-72706c66bf5b","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field fba671e1-7df1-4928-8870-ba5928045da8 --><h3>What is the initial management of a person presenting with pityriasis versicolor?</h3><!-- end field fba671e1-7df1-4928-8870-ba5928045da8 -->","summary":null,"htmlStringContent":"<!-- begin item eb7b6a7c-e18d-4dc5-980b-1876e71610de --><!-- begin field 1697f499-3bcd-45c9-b4e3-35d5fd6da37b --><ul><li><strong>Advise the person that: </strong><ul><li>Pityriasis versicolor is not contagious as the yeast that causes it is normally present on human skin — infection is not due to poor hygiene.</li><li>Treatment is usually highly effective, but may need to be repeated, as recurrence is common (especially in the summer months).</li><li>Following successful treatment skin discolouration may take several weeks or months to fully resolve.</li><li>Further information and support is available in the <a data-hyperlink-id=\"ffe9ddfd-f66d-45ac-92f1-aba000a5648e\" href=\"https://www.bad.org.uk/\" rel=\"noopener\" target=\"_blank\">British Association of Dermatology</a> patient information leaflet <a data-hyperlink-id=\"17593404-c8a7-462b-ab5d-aba000a5650f\" href=\"https://www.skinhealthinfo.org.uk/condition/pityriasis-versicolor/\" rel=\"noopener\" target=\"_blank\">Pityriasis versicolor</a>.</li></ul></li><li><strong>If an extensive area is involved, prescribe an antifungal shampoo such as:</strong><ul><li><strong>Ketoconazole 2% shampoo:</strong><ul><li>For children aged 12–17 years and adults apply once daily for up to 5 days — the preparation should be lathered and left on affected skin for 3–5 minutes before thoroughly rinsing off.</li></ul></li><li><strong>Selenium sulphide 2.5% shampoo</strong> <strong>(off-label):</strong><ul><li>Selenium sulphide shampoo is commonly used, but this is an off-label indication. It is contraindicated in pregnancy.</li><li>For non-pregnant adults apply once daily for 7 days (one or two applications may be sufficient) — the preparation should be lathered and left on affected skin for 10 minutes before thoroughly rinsing off.</li><li>Selenium sulphide shampoo is more likely to cause skin dryness and irritation than ketoconazole shampoo. Dilution with a small amount of water before application may reduce irritation.</li></ul></li></ul></li><li><strong>If only small areas are involved, consider prescribing an antifungal cream as an alternative.</strong><ul><li>Imidazole creams (such as clotrimazole [preferred in pregnancy], econazole, or ketoconazole) can be applied twice a day for up to 2–3 weeks.</li></ul></li><li><strong>Do not prescribe topical or oral corticosteroids.</strong></li><li><strong>If initial topical treatment fails, or if pityriasis versicolor is widespread, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/pityriasis-versicolor/management/management/#treatment-failure\">treatment failure</a>.</strong></li></ul><!-- end field 1697f499-3bcd-45c9-b4e3-35d5fd6da37b --><!-- end item eb7b6a7c-e18d-4dc5-980b-1876e71610de -->","subChapters":[{"id":"2735fc4b-79fc-5c02-b135-91981ce52c6f","slug":"basis-for-recommendation-986","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 23896b53-e07f-49b5-a1ec-2455a354a5ef --><h4>Basis for recommendation</h4><!-- end field 23896b53-e07f-49b5-a1ec-2455a354a5ef -->","summary":null,"htmlStringContent":"<!-- begin item 98660eed-e689-41b1-b55f-816dfb95ae7f --><!-- begin field 47b2790b-bf22-44cd-a87d-28a784f82012 --><h5>Initial information and advice</h5><ul><li>These recommendations are based on expert opinion in clinical guidance <em>Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hald, 2015</a>] and <em>Pityriasis versicolor</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PCDS, 2019</a>], and expert opinion in a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>], a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Bamford, 2014</a>], and a British Association of Dermatologists patient information leaflet [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BAD, 2017</a>].</li></ul><h5>Topical antifungal shampoos</h5><ul><li>Recommendations on use of topical antifungal shampoos are based on expert opinion in clinical guidance <em>Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hald, 2015</a>], <em>Fungal skin and nail infections: diagnosis and laboratory investigation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PHE, 2017</a>], <em>Antifungal agents for common outpatient paediatric infections</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Canadian Paediatric Society, 2019</a>], and <em>Pityriasis versicolor </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PCDS, 2019</a>]; expert opinion in a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>]; and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Gupta, 2015</a>].<ul><li>Ketoconazole shampoo or selenium sulphide shampoo as an alternative are widely recommended in the literature as first-line treatment for pityriasis versicolor [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Gupta, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hald, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PHE, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Canadian Paediatric Society, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PCDS, 2019</a>]. CKS found insufficient evidence on the relative efficacy of either ketoconazole shampoo or selenium sulphide shampoo in the treatment of pityriasis versicolor to recommend one treatment over the other.</li><li>Ketoconazole is the most extensively studied drug treatment. In one meta-analysis (n = 742), topical ketoconazole was associated with a mycological eradication rate of 65% compared with 45% for topical terbinafine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hu, 2010</a>].</li><li>Recommended treatment regimens are based on expert opinion in clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PHE, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PCDS, 2019</a>], a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>].</li></ul></li></ul><h5>Topical imidazole antifungal creams</h5><ul><li>Recommendations on use of topical antifungal creams are based on clinical guidance <em>Fungal skin and nail infections: diagnosis and laboratory investigation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PHE, 2017</a>] and <em>Antifungal agents for common outpatient paediatric infections</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Canadian Paediatric Society, 2019</a>], expert opinion in a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>], a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Gupta, 2015</a>], prescribing information from the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>], and Summaries of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019a</a>].        </li><li>Topical antifungal creams (such as clotrimazole, econazole, or ketoconazole) may be impractical to use if a wide body surface area is affected [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>].<ul><li>One systematic review (n = 868), which looked at studies up to 2009 comparing different topical treatments for pityriasis versicolor, found that shampoos are preferred to creams, as creams are less cost-effective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hu, 2010</a>].</li><li>One double-blind randomized controlled trial (n = 120) compared twice-daily topical clotrimazole (and placebo capsule) with single-dose oral fluconazole (and placebo cream) taken for 2 weeks. After 4 weeks, the rate of full resolution favoured the topical clotrimazole group (94.9% versus 81.2%, p = 0.04) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Dehghan, 2010</a>].</li></ul></li></ul><h5>Corticosteroids not recommended</h5><ul><li>Topical or oral corticosteroids are not recommended as there is not usually a significant inflammatory component. They may exacerbate the condition and cause skin atrophy.</li><li>A US study of nearly 3 million visits found that corticosteroids were sometimes inappropriately prescribed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Mellen, 2004</a>]. Hydrocortisone was prescribed in nearly 30,000 visits where there was no diagnosis other than pityriasis versicolor. Betamethasone dipropionate/clotrimazole combinations were used in over 66,000 visits.</li></ul><!-- end field 47b2790b-bf22-44cd-a87d-28a784f82012 --><!-- end item 98660eed-e689-41b1-b55f-816dfb95ae7f -->","subChapters":[]}]},{"id":"7a01dcdb-1b56-5cfe-bc8c-bdd56be884c6","slug":"preventing-recurrence","fullItemName":"Preventing recurrence","depth":3,"htmlHeader":"<!-- begin field f6880b3d-ebef-4f1f-b732-4a82b104a9b6 --><h3>How can I prevent recurrence of pityriasis versicolor?</h3><!-- end field f6880b3d-ebef-4f1f-b732-4a82b104a9b6 -->","summary":null,"htmlStringContent":"<!-- begin item f62ec96a-6c25-4890-85ef-3f2e697ecd30 --><!-- begin field dd767312-227f-479c-b5d1-b62b8e841563 --><ul><li><strong>Relapse is common and in most cases re-treatment of each episode as for the <strong><a class=\"topic-reference external-reference\" href=\"/topics/pityriasis-rosea/management/management/#management-in-primary-care\">initial presentation</a></strong> is appropriate.</strong><ul><li>Alternatively, ketoconazole shampoo once every 2–4 weeks for up to 6 months for prevention of recurrence can be considered.</li><li>Ensure the person is aware that re-pigmentation can take several months following successful treatment.</li></ul></li><li><strong>If </strong><strong>episodes of pityriasis versicolor recur on exposure to warm, humid environments or sunshine,</strong><strong> prophylactic treatment prior to exposure (for example before travel abroad) can be considered.</strong><ul><li>For children over 12 years of age and adults, apply ketoconazole 2% shampoo once daily for a maximum of 3 days prior to sun exposure. When applying the shampoo, lather, and leave it on for 3–5 minutes, before thoroughly rinsing off.</li></ul></li></ul><!-- end field dd767312-227f-479c-b5d1-b62b8e841563 --><!-- end item f62ec96a-6c25-4890-85ef-3f2e697ecd30 -->","subChapters":[{"id":"601b9143-e401-5bb9-87bd-8365b3b8c17d","slug":"basis-for-recommendation-514","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 94d08e00-9cb1-4e3e-b8e2-6414885eecca --><h4>Basis for recommendation</h4><!-- end field 94d08e00-9cb1-4e3e-b8e2-6414885eecca -->","summary":null,"htmlStringContent":"<!-- begin item 514ab0b2-569c-4baa-8e4e-a8a904b8f6e8 --><!-- begin field 3a4e8c0f-e6fe-4ba4-8380-82b4db37342c --><h5>Prevention of recurrence</h5><ul><li>Relapse is common – expert opinion in a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>] is that re‐treatment of each episode is preferable to long‐term suppressive therapy. It is important to ensure that the person understands that repigmentation may take several months following successful treatment and that this persistence of hypopigmentation does not indicate treatment failure.</li><li>Guidance from the Primary Care Dermatological Society (PCDS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PCDS, 2019</a>] on recurrent infection is that ketoconazole shampoo should be continued once every 2–4 weeks for up to 6 months after re-treatment with initial therapy has been completed.</li><li>The use of ketoconazole 2% shampoo as a prophylactic treatment prior to sun exposure is a licensed indication, based on the manufacturer’s Summary of Product Characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019b</a>] and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>].</li></ul><!-- end field 3a4e8c0f-e6fe-4ba4-8380-82b4db37342c --><!-- end item 514ab0b2-569c-4baa-8e4e-a8a904b8f6e8 -->","subChapters":[]}]},{"id":"a1144771-2cb8-5796-a4d4-f1a1efbf6e16","slug":"pregnancy-or-breastfeeding","fullItemName":"Pregnancy or breastfeeding","depth":3,"htmlHeader":"<!-- begin field a3911dc7-8d1b-4b31-803e-80950594beb6 --><h3>How should I treat a pregnant or breastfeeding woman?</h3><!-- end field a3911dc7-8d1b-4b31-803e-80950594beb6 -->","summary":null,"htmlStringContent":"<!-- begin item 13411659-a15c-4333-a94e-498ac91f4c01 --><!-- begin field a8eafb3f-69e3-4b34-8e80-85398218688c --><div><ul><li><strong>Pregnancy</strong><ul><li>Use clotrimazole cream (preferred) or ketoconazole shampoo where indicated.</li><li>Selenium sulphide shampoo is not recommended and should be avoided in pregnancy.</li><li>Oral anti-fungal treatments (such as fluconazole or itraconazole) are not recommended and should be avoided in pregnancy.</li></ul></li><li><strong>Breastfeeding</strong><ul><li>Ketoconazole 2% shampoo or clotrimazole cream may be considered where indicated — care should be taken to ensure topical agents are not applied to the nipple or surrounding area.</li><li>Selenium sulphide shampoo is not recommended and should be avoided in breastfeeding.</li><li>Oral anti-fungal treatments (such as fluconazole or itraconazole) are not recommended and should be avoided in breastfeeding.</li></ul></li></ul></div><!-- end field a8eafb3f-69e3-4b34-8e80-85398218688c --><!-- end item 13411659-a15c-4333-a94e-498ac91f4c01 -->","subChapters":[{"id":"f4336ed5-b199-5b51-8c59-528d3b87b37a","slug":"basis-for-recommendation-d70","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field bae14ad5-154f-4641-8991-1bfc4fba342b --><h4>Basis for recommendation</h4><!-- end field bae14ad5-154f-4641-8991-1bfc4fba342b -->","summary":null,"htmlStringContent":"<!-- begin item d703a0b7-1696-4cd5-8811-8ff50eee3d0d --><!-- begin field 61670517-c3da-4e2a-80e9-68e6194c2d3a --><p>The recommendations on treating pityriasis versicolor during pregnancy and breastfeeding are based on information published by the UK Teratology Information Service (UKTIS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">UKTIS, 2018</a>], a drugs in lactation database [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">LactMed, 2018a</a>], and the manufacturers’ Summary of Product Characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019c</a>].</p><h5>Pregnancy</h5><ul><li>Clotrimazole cream — may be used during pregnancy if required. Most data relate to its use in the treatment of vulvovaginal candidiasis in pregnancy and suggest that exposure to clotrimazole during pregnancy does not increase the overall risk of congenital malformation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">UKTIS, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>].</li><li>Topical econazole — is not recommended for use in pregnancy owing to insufficient data on safety in human pregnancies compared with clotrimazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019a</a>].</li><li>Ketoconazole 2% shampoo — there are no known risks associated with the use of ketoconazole 2% shampoo in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019b</a>]. However, it is noted that ketoconazole inhibits several enzymes involved in the synthesis of adrenal and testicular steroid hormones, and teratogenicity has been reported in animal studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Micromedex, 2015</a>]. Systemic absorption of ketoconazole from the skin is poor, but plasma levels of ketoconazole are detectable after topical administration of ketoconazole shampoo to the whole body [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019b</a>]. Therefore, a small risk cannot be excluded but a high risk of congenital abnormalities seems unlikely.</li><li>There are no data on the safety of selenium sulphide shampoo in pregnancy — the manufacturer states that it should be avoided during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019c</a>].</li><li>Oral fluconazole is <em>not</em> recommended for use by pregnant women, particularly in the first trimester, because long-term treatment with higher doses of oral fluconazole (400 mg to 800 mg per day) have been associated with craniofacial, skeletal, and cardiac malformations in the infant. Data on risks associated with lower doses are lacking [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">UKTIS, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI 2018</a>].</li><li>Oral itraconazole is <em>not</em> recommended for use by pregnant women. Teratogenicity has been reported in animal studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Micromedex, 2015</a>]. During post-marketing experience, cases of congenital malformations (including skeletal, genitourinary tract, cardiovascular, and ophthalmic malformations, as well as chromosomal and multiple malformations) have been reported [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2018a</a>].</li></ul><h5>Breastfeeding</h5><ul><li>Ketoconazole 2% shampoo — levels of ketoconazole in breast milk are likely to be very small following use of ketoconazole shampoo. Systemic absorption of ketoconazole from the skin is poor, but plasma levels of ketoconazole are detectable after topical administration of ketoconazole shampoo to the whole body. Topical use on the breast or nipples should be avoided in nursing mothers because of possible oral ingestion by the infant [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">LactMed, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019b</a>].</li><li>Selenium sulphide shampoo — there are no data on the safety of selenium sulphide shampoo in breastfeeding — the manufacturer recommends that it is avoided during breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019c</a>].</li><li>Clotrimazole — clotrimazole is minimally absorbed via the skin and levels in breast milk are likely to be very small following topical use. Excess cream should be removed from the nipples before nursing. Only water-miscible cream or gel products should be applied to the breast because ointments may expose the infant to high levels of mineral paraffins via licking [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">LactMed, 2018c</a>].</li><li>Econazole — there are limited data on the use of topical econazole in breastfeeding. The manufacturer states that a risk to the breast-fed child cannot be excluded [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2019a</a>].</li><li>Fluconazole — is excreted into breast milk in significant amounts, but the concentration is less than the neonatal fluconazole dosage [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">LactMed, 2018a</a>]. The NHS Specialist Pharmacy Service (SPS) advise caution with use in mothers breastfeeding preterm infants as there is no direct evidence of safety and limited clinical experience [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">SPS, 2018</a>].</li><li>There is little experience with itraconazole in women who are breastfeeding. Small amounts of itraconazole are excreted into breast milk, and the manufacturer advises that it should be avoided in women who are breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2018a</a>].</li></ul><!-- end field 61670517-c3da-4e2a-80e9-68e6194c2d3a --><!-- end item d703a0b7-1696-4cd5-8811-8ff50eee3d0d -->","subChapters":[]}]},{"id":"7b795d4c-8729-50cf-a3aa-c0bd3fad1a03","slug":"treatment-failure","fullItemName":"Treatment failure","depth":3,"htmlHeader":"<!-- begin field 3cb14b03-1e5f-4768-a35c-8529eb7da2da --><h3>How should I manage treatment failure?</h3><!-- end field 3cb14b03-1e5f-4768-a35c-8529eb7da2da -->","summary":null,"htmlStringContent":"<!-- begin item cc9a87db-b04e-45ac-8992-bc2187a677fd --><!-- begin field 4cd6fb90-4339-42cb-ac33-f13f963051ee --><ul><li><strong>If initial topical treatment fails, confirm that the treatment regimen has been followed adequately. </strong><ul><li>Changes in skin pigmentation usually fully resolve within 2–3 months of starting antifungal treatment (but may persist for longer). Persisting pale patches in the absence of other signs or positive mycology are not necessarily an indication for further treatment.</li></ul></li><li><strong>Consider if <a class=\"topic-reference internal-reference\" href=\"/topics/pityriasis-versicolor/management/management/#referral\">referral</a> to a dermatologist is required </strong>(especially in children younger than 12 years of age and pregnant or breastfeeding women).</li><li><strong>Consider a second-line <a class=\"topic-reference internal-reference\" href=\"/topics/pityriasis-versicolor/management/management/#initial-management\">topical antifungal treatment</a></strong> (for example selenium sulphide shampoo if ketoconazole shampoo was used first line).<ul><li>For further information, see the <a class=\"topic-reference internal-reference\" href=\"/topics/pityriasis-versicolor/prescribing-information/\">Prescribing</a> section.</li></ul></li><li><strong>Consider taking <a class=\"topic-reference internal-reference\" href=\"/topics/pityriasis-versicolor/management/management/#additional-information\">skin scrapings</a> for microscopy to confirm the diagnosis of pityriasis versicolor, if: </strong><ul><li>The diagnosis is uncertain.</li><li>The skin lesions do not respond to topical antifungal treatment.</li><li>Oral antifungal treatment is being considered.</li></ul></li><li><strong><strong>If topical treatment is ineffective and confident of the diagnosis, consider offering an oral antifungal drug,</strong> such as itraconazole or fluconazole: </strong><ul><li><strong>For adults (not pregnant),</strong> itraconazole 200 mg once daily for 7 days; or fluconazole 50 mg once daily for 2–4 weeks.</li><li><strong>For pregnant or breastfeeding women and children, </strong>seek specialist advice.</li></ul></li></ul><!-- end field 4cd6fb90-4339-42cb-ac33-f13f963051ee --><!-- end item cc9a87db-b04e-45ac-8992-bc2187a677fd -->","subChapters":[{"id":"561225f1-01f0-5c46-a714-0a64c89aa868","slug":"additional-information","fullItemName":"Additional information","depth":4,"htmlHeader":"<!-- begin field 1b494f26-ad71-4454-bbb7-3e3f05aebb12 --><h4>Additional information</h4><!-- end field 1b494f26-ad71-4454-bbb7-3e3f05aebb12 -->","summary":null,"htmlStringContent":"<!-- begin item 99f8a485-8793-4690-9b00-e1b345085e81 --><!-- begin field 16dec435-4d46-4ee4-9344-324b10f472ae --><ul><li><strong>To take skin scrapings for microscopy:</strong><ul><li>Wipe off any creams before sampling.</li><li>Carefully scrape skin from the patches, using a scalpel blade or similar implement (such as a skin scraper). A larger number of microorganisms are most likely to be found in the advancing edge of the patch.</li><li>Collect as many skin scales as possible (ideally 5 mm<sup>2</sup>).</li><li>Collect the sample into folded dark paper squares (secure with a paper clip), or use a commercially-available fungal pack (such as Mycotrans® or Dermapack®). This keeps the specimen dry, and prevents overgrowth of bacterial contaminants. Do not use plastic containers as the skin scales adhere to the sides and are difficult to remove.</li></ul></li><li><strong>If very little scale is present and insufficient material can be collected by scraping, skin strippings can be taken:</strong><ul><li>Apply transparent waterproof adhesive tape to the infected area, peel off and stick to a sterile microscope slide for examination.</li></ul></li><li><strong>Send the sample to the laboratory for microscopy,</strong> ensuring that clinical details are stated, including any treatment received and overseas travel history.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Schwartz, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PHE, 2017</a>]</p><!-- end field 16dec435-4d46-4ee4-9344-324b10f472ae --><!-- end item 99f8a485-8793-4690-9b00-e1b345085e81 -->","subChapters":[]},{"id":"bdd74bd5-b5e3-5a4e-8dee-bff418db8e1e","slug":"basis-for-recommendation-c2c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 496b87e0-419c-4efb-ab3f-8c7211c1d028 --><h4>Basis for recommendation</h4><!-- end field 496b87e0-419c-4efb-ab3f-8c7211c1d028 -->","summary":null,"htmlStringContent":"<!-- begin item c2ca16b4-f509-4976-9615-14a71b95eebd --><!-- begin field d0e545ae-8f4a-4cf3-a617-cca305432a0e --><h5>Second-line topical antifungal treatment</h5><ul><li>The recommendation to try a second-line antifungal treatment before considering oral antifungal treatment is based on the expert opinion of previous external reviewers of this CKS topic.</li></ul><h5>Oral antifungal treatment</h5><ul><li>The recommendations on oral antifungal treatment are based on clinical guidance <em>Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hald, 2015</a>] and <em>Fungal skin and nail infections: diagnosis and laboratory investigation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PHE, 2017</a>], expert opinion in a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>], a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Gupta, 2015</a>], the manufacturers’ Summary of Product Characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2018a</a>], and information in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>].<ul><li>Randomized controlled trials (RCTs) of oral antifungal treatments for pityriasis versicolor are generally of low quality and small. Trials comparing the efficacy of different preparations and regimens tend to be underpowered to detect clinically meaningful differences. The available data suggest that oral antifungals are effective when compared with placebo with numbers needed to treat (NNTs) of 2 or greater [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hu, 2010</a>]. Insufficient trial-based evidence means it is not possible to recommend one drug or dosage regimen over another.</li></ul></li></ul><h5>Skin scrapings for microscopy</h5><ul><li>The recommendation on the use of microscopy is based on guidance from Public Health England [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PHE, 2017</a>], expert opinion in a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>], and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Bamford, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Gupta, 2015</a>].</li></ul><!-- end field d0e545ae-8f4a-4cf3-a617-cca305432a0e --><!-- end item c2ca16b4-f509-4976-9615-14a71b95eebd -->","subChapters":[]}]},{"id":"99ff5852-26b4-5b46-b099-e945b22c1771","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field cae52d2a-09f2-4eae-b2ca-fafca9ffd027 --><h3>When should I refer a person with pityriasis versicolor?</h3><!-- end field cae52d2a-09f2-4eae-b2ca-fafca9ffd027 -->","summary":null,"htmlStringContent":"<!-- begin item b9fb368a-99d6-4425-91fb-68bc6b341439 --><!-- begin field 5e03ed13-a404-4c88-a0c2-bdad5f7bb775 --><ul><li><strong>Consider referral to a dermatologist if:</strong><ul><li>The diagnosis is uncertain or <a class=\"topic-reference internal-reference\" href=\"/topics/pityriasis-versicolor/management/management/#additional-information\">skin scraping</a> microscopy is negative.<ul><li>A specialist Wood's light examination may help with the diagnosis, as patches fluoresce with a characteristically yellow/green fluorescence. However, a Wood’s light examination is positive in only about a third of people with pityriasis versicolor and is not usually available in primary care.</li></ul></li><li>There is an inadequate response to optimal treatment in primary care.</li><li>Pityriasis versicolor is severe or very extensive.</li><li>The person is a child or pregnant woman, where management options are limited in primary care.</li><li>The person is immunocompromized, depending on clinical judgement.</li><li>Long-term oral antifungal prophylaxis may be needed for recurrent or severe episodes of pityriasis versicolor.</li></ul></li></ul><!-- end field 5e03ed13-a404-4c88-a0c2-bdad5f7bb775 --><!-- end item b9fb368a-99d6-4425-91fb-68bc6b341439 -->","subChapters":[{"id":"8e0ecfb9-217d-561f-8b0b-2a429e5680e9","slug":"basis-for-recommendation-25e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a7e69b17-7bf2-499e-9c6d-37763e174a6f --><h4>Basis for recommendation</h4><!-- end field a7e69b17-7bf2-499e-9c6d-37763e174a6f -->","summary":null,"htmlStringContent":"<!-- begin item 25efa2e5-702d-4ebf-b971-d67993a7fb4a --><!-- begin field a609cdc1-bd95-4c24-8625-c178446167e7 --><p>The recommendations on referral are pragmatic based on what CKS considers to be good clinical practice.</p><h5>Specialist Wood's light examination </h5><ul><li>A Wood's light is a portable quartz lamp emitting filtered long-wave ultraviolet light. Examination in a darkened room is positive for fluorescence in a third to a half of people; infection is frequently caused by non-fluorescent species. Information on the use of the Wood's light is based on expert opinion in clinical guidance <em>Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hald, 2015</a>] and <em>Pityriasis versicolor</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">PCDS, 2018</a>], a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hay, 2016</a>],  and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Gupta, 2015</a>].</li></ul><h5>Children and pregnant women</h5><ul><li>The recommendation on considering specialist advice for children and pregnant women is based on use of some treatments (such as oral antifungals) being off-label in these groups [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>].</li></ul><h5>Long-term antifungal prophylaxis</h5><ul><li>The information on long-term prophylactic treatment for people with recurrent or severe episodes of pityriasis versicolor is based on expert opinion in clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hald, 2015</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Hu, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Gupta, 2015</a>].</li><li>Recurrent pityriasis versicolor may indicate another underlying cause, which may require specialist investigation.</li></ul><!-- end field a609cdc1-bd95-4c24-8625-c178446167e7 --><!-- end item 25efa2e5-702d-4ebf-b971-d67993a7fb4a -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}